Bipolar Disorder Market Size, Share, Growth Analysis, By Drug Class(Mood Stabilizers, Anticonvulsants, Antipsychotic Drugs, Antidepressant Drugs), By Type(Bipolar I Disorder, Bipolar II Disorder, Cyclothymic Disorder, Others), By Region - Industry Forecast 2024-2031

Bipolar Disorder Market Drivers

Emphasis on improving product portfolio and the growing number of mental illnesses is expected to propel the market growth

• The market for treating bipolar illness is anticipated to rise over the forecast period as key players concentrate on expanding their product portfolio through an increase in the launches and approvals of new pharmaceuticals for the condition. For instance, in May 2019, the U.S. Food and Drug Administration (FDA) approved Allergan plc and Gedeon Richter plc's supplemental new drug application (sNDA) for VRAYLAR (cariprazine), an oral, once-daily atypical antipsychotic drug for the expanded use and treatment of depressive episodes related to bipolar I disorder (bipolar depression) in adults.
• Bipolar disorder prevalence is rising, there are more government efforts to raise public awareness of its consequences, there is a strong demand for antidepressants, and there is a desire to lessen the illness burden of bipolar disorder. 

Bipolar Disorder Market Restraints

Lack of medications and the correct line of treatment to create market challenges

• The patent expirations of several key products, including Latuda (lurasidone) from Sumitomo Dainippon Pharma and Sunovion Pharmaceuticals, Abilify Maintena (aripiprazole ER) from Otsuka Pharmaceutical and Lundbeck, and Risperdal Consta (risperidone PR) from Johnson and Johnson, are expected to further increase the constraints in the bipolar disorder market during the forecast period. Lithium is one example of a generic drug with high usage that is anticipated to last the entire projected period.
• Lack of appropriate diagnostic methods for the diagnosis of the disease and the negative side effects of treatments for bipolar disorder are anticipated to restrain market expansion. On the other hand, developments in drug combination therapy offer profitable prospects for market expansion in the near future.